For tumours with moderate levels of baseline TILs, PD-1 checkpoint blockade confers additional anti-tumour activity in combination with the olaparib and WEE1 inhibition, even at reduced doses, to achieve more durable anti-tumour efficacy. The gene discussed is WEE1; the disease is neoplasm.